-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

APHEXDA (motixafortide): Learn about this new FDA approved treatment option

Sponsor: BioLineRx, Inc.
Program: Product Theaters
Sunday, December 10, 2023: 8:00 AM-9:00 AM
Room 3 (San Diego Convention Center)
Owen Lockerbie, PhD, BioLineRx and Michael Riotto, Patient Advocate
No relevant conflicts of interest to declare.
For In-Person Participants Only
See more of: Product Theaters